These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 3091231)

  • 21. Association Between the Serum Carnitine Level and Ammonia and Valproic Acid Levels in Patients with Bipolar Disorder.
    Yokoyama S; Yasui-Furukori N; Nakagami T; Miyazaki K; Ishioka M; Tarakita N; Kubo K; Sugawara N; Shimoda K
    Ther Drug Monit; 2020 Oct; 42(5):766-770. PubMed ID: 32482992
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The risk of asymptomatic hyperammonemia in children with idiopathic epilepsy treated with valproate: relationship to blood carnitine status.
    Hamed SA; Abdella MM
    Epilepsy Res; 2009 Sep; 86(1):32-41. PubMed ID: 19446440
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Blood ammonia level during valproic acid therapy.
    Kugoh T; Yamamoto M; Hosokawa K
    Jpn J Psychiatry Neurol; 1986 Dec; 40(4):663-8. PubMed ID: 3110472
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lack of relationship between sodium valproate-induced adverse effects and the plasma concentration of its metabolite 2-propylpenten-4-oic acid.
    Paganini M; Zaccara G; Moroni F; Campostrini R; Bendoni L; Arnetoli G; Zappoli R
    Eur J Clin Pharmacol; 1987; 32(2):219-22. PubMed ID: 3108013
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Hyperammonemia in valproate therapy in children and adolescents].
    Laub MC
    Nervenarzt; 1986 May; 57(5):314-8. PubMed ID: 3088461
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacokinetics and clinical application of intravenous valproate in Thai epileptic children.
    Visudtibhan A; Bhudhisawadi K; Vaewpanich J; Chulavatnatol S; Kaojareon S
    Brain Dev; 2011 Mar; 33(3):189-94. PubMed ID: 20444563
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of Carbamazepine and Valproate on Serum Aspartate Aminotransferase, Alanine Aminotransferase and Gamma - Glutamyltransferase in Children.
    Hadzagic-Catibusic F; Hasanbegovic E; Melunovic M; Zubcevic S; Uzicanin S
    Med Arch; 2017 Aug; 71(4):239-242. PubMed ID: 28974841
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Potential relationships between transaminase abnormality and valproic acid clearance or serum carnitine concentrations in Japanese epileptic patients.
    Goto S; Seo T; Hagiwara T; Ueda K; Yamauchi T; Nagata S; Ando Y; Ishitsu T; Nakagawa K
    J Pharm Pharmacol; 2008 Feb; 60(2):267-72. PubMed ID: 18237476
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Gait instability in valproate-treated patients: Call to measure ammonia levels.
    Kipervasser S; Elger CE; Korczyn AD; Nass RD; Quesada CM; Neufeld MY
    Acta Neurol Scand; 2017 Nov; 136(5):401-406. PubMed ID: 28436001
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sodium valproate-induced hyperammonemia without clinical hepatic dysfunction.
    Zaret BS; Beckner RR; Marini AM; Wagle W; Passarelli C
    Neurology; 1982 Feb; 32(2):206-8. PubMed ID: 6798491
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Therapy of infantile spasms with valproate: results of a prospective study.
    Siemes H; Spohr HL; Michael T; Nau H
    Epilepsia; 1988; 29(5):553-60. PubMed ID: 2842127
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Incidence of pathologic ammonia concentrations in the plasma in children with seizure disorders treated with Convulsofin/Convulex and other anticonvulsants in comparison with children with brain damage and healthy children].
    Wiedemann G; Haupt M; Rommel A; Rommel KF; Biesenbach R; Schmidt W
    Kinderarztl Prax; 1990 Jan; 58(1):21-7. PubMed ID: 2110274
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of UGT2B7, SCN1A and CYP3A4 on the therapeutic response of sodium valproate treatment in children with generalized seizures.
    Feng W; Mei S; Zhu L; Yu Y; Yang W; Gao B; Wu X; Zhao Z; Fang F
    Seizure; 2018 May; 58():96-100. PubMed ID: 29679912
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Measurement of levetiracetam drug levels to assist with seizure control and monitoring of drug interactions with other anti-epileptic medications (AEMs).
    Stepanova D; Beran RG
    Seizure; 2014 May; 23(5):371-6. PubMed ID: 24630809
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Determinants of free serum valproate concentration: A prospective study in patients on divalproex sodium monotherapy.
    Nasreddine W; Dirani M; Atweh S; Makki A; Beydoun A
    Seizure; 2018 Jul; 59():24-27. PubMed ID: 29730272
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Valproic acid monotherapy induces DNA oxidative damage.
    Schulpis KH; Lazaropoulou C; Regoutas S; Karikas GA; Margeli A; Tsakiris S; Papassotiriou I
    Toxicology; 2006 Jan; 217(2-3):228-32. PubMed ID: 16289809
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical and pharmacokinetic observations on sodium valproate - a 5-year follow-up study in 100 children with epilepsy.
    Henriksen O; Johannessen SI
    Acta Neurol Scand; 1982 May; 65(5):504-23. PubMed ID: 6810648
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of serum albumin on free fractions of phenobarbital and valproic acid in patients with convulsive seizures.
    Sadahiro N; Kodama S; Matsui T; Komatsu M; Matsuo T
    Brain Dev; 1985; 7(4):377-84. PubMed ID: 3933372
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Serum valproate concentrations in epileptic children with favourable responses.
    Ishikawa T; Ogino C; Furuyama M; Kanayama M; Awaya A; Yamaguchi A
    Brain Dev; 1987; 9(3):283-7. PubMed ID: 3116876
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Low and variable presence of valproic acid in human brain.
    Shen DD; Ojemann GA; Rapport RL; Dills RL; Friel PN; Levy RH
    Neurology; 1992 Mar; 42(3 Pt 1):582-5. PubMed ID: 1549218
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.